#United States #Veeva Systems #Pleasanton #Veeva AI #Falcon AI

Veeva Launches Falcon: Redefining Drug Development with AI

In an exciting development for the life sciences industry, Veeva Systems, a leading pioneer in SaaS solutions, has introduced a groundbreaking platform and standard AI agent known as Veeva Falcon. Scheduled for release on May 27, 2026, this innovative AI-driven agent aims to transform drug development processes significantly by leveraging autonomous AI technology. This move aligns with Veeva's mission to enhance efficiency, reduce costs, and bolster compliance for biopharmaceutical companies of all sizes.

The Functionality of Veeva Falcon

Veeva Falcon is designed to seamlessly integrate with various applications on the Veeva Development Cloud, including clinical trials, regulatory submissions, and safety information management solutions. Its core capabilities focus on key aspects of drug development, such as:

• - Document Management: Efficiently importing documents for clinical trial master files while ensuring quality control.
• - Regulatory Interactions: Facilitating streamlined communications with regulatory authorities during the approval process.
• - Safety Information Management: Enhancing case triage and intake processes within safety information management.

By automating these critical tasks, Veeva Falcon is set to drive significant improvements in productivity and accelerate the overall drug development timeline.

Vision from Veeva Leadership

Peter Gassner, founder and CEO of Veeva Systems, highlighted the strategic importance of Falcon in the company’s portfolio. He expressed enthusiasm about its capabilities, stating, "Falcon represents a significant commitment for Veeva, marking our first foray into autonomous AI-driven operations. We look forward to working with our clients to reduce costs and enhance speed across the industry through Falcon."

This innovative solution is part of Veeva's wider Veeva AI initiative, which is tailored specifically for the life sciences sector. By incorporating artificial intelligence into their offerings, Veeva aims to empower organizations to make data-driven decisions and improve product development strategies.

Anticipated Launch and Adoption

Veeva Falcon is scheduled for roll-out to early adopter customers in November 2026, positioning it at the forefront of next-generation AI applications within the pharmaceutical development landscape. This launch will not only set new standards for operational efficiency but also align with industry needs for increased agility and compliance in drug development.

About Veeva Systems

Veeva is committed to providing cloud services specializing in the life sciences sector through innovative software, AI, and data solutions. With a focus on customer success and product excellence, Veeva serves over 1,500 clients, ranging from the world's largest biopharmaceutical companies to emerging biotech firms. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the broader industry.

For more information about Veeva, visit www.veeva.com/jp/.

Important Disclaimer

This article contains forward-looking statements regarding Veeva’s products and expected benefits. Actual results could differ materially from those described, and the company has no obligation to update such statements. Risks and uncertainties related to Veeva’s business can be found in their filings, including Form 10-K.

To stay updated on Veeva’s latest developments, connect with us on LinkedIn.